Leukemia Treatment India

World-class leukemia treatment in India, coordinated by MediGoCare for international patients

Last Updated: July 2026 | Reviewed by: MediGoCare Medical Team

Getting a leukemia diagnosis is terrifying. But choosing where to get treated shouldn't add more fear on top of that.

We work with blood cancer patients at MediGoCare every single month — from Nigeria, Bangladesh, Nepal, Tanzania, the UAE, Kenya, and beyond. And the one thing we hear over and over again is: "I didn't know India had treatment this good at this price."

So let's fix that. This page tells you everything — what type of leukemia you have, what treatments exist in India, what they actually cost in 2026, which hospitals lead in outcomes, and exactly how we help you get there without stress.

What Is Leukemia? The 4 Types India's Hospitals Treat

Leukemia is a cancer of the blood and bone marrow. It starts when abnormal white blood cells multiply out of control — crowding out the healthy blood cells your body needs to fight infections, carry oxygen, and stop bleeding. But not all leukaemias are the same. There are four main types, and each one needs a different treatment approach.

India's haematology centres are experienced in treating all four — and we'll walk you through each one.

Acute Lymphoblastic Leukaemia (ALL) — Most Common in Children

ALL is the most common childhood cancer. It moves fast. That's the scary part. But here's the encouraging truth: with modern chemotherapy, paediatric ALL has one of the highest cure rates of any cancer. India's top centres report 5-year survival rates of 70–85% in children.

ALL in adults is more challenging, but India's haematologists follow the same NCCN and ESMO protocols used at Harvard Medical School or the Royal Marsden. For patients who relapse, CAR-T cell therapy is now available in India — and that's genuinely a game changer.

Acute Myeloid Leukaemia (AML) — Moves Fast, Needs Fast Action

AML grows rapidly and needs treatment urgently. It's more common in adults over 40. The standard approach is intensive induction chemotherapy to push the disease into remission, followed by consolidation, and often a bone marrow transplant for eligible patients.

In our experience coordinating AML cases, speed matters enormously. India's advantage here is real — patients can start treatment within 10–14 days of arriving, while waiting times for the same treatment in the NHS can stretch beyond 12 weeks.

Peer-reviewed data from PubMed shows that AML in first remission at India's top BMT centres achieves 55–65% 5-year survival — comparable to outcomes in the USA.

Chronic Myeloid Leukaemia (CML) — Highly Manageable with the Right Drug

CML is driven by one genetic mutation — the BCR-ABL gene. And that's actually good news. Why? Because it means one class of drugs — Tyrosine Kinase Inhibitors (TKIs) — targets that mutation directly and works brilliantly for most patients.

Imatinib, dasatinib, nilotinib, bosutinib, ponatinib — India manufactures high-quality generic versions of all of them. Monthly cost in India: $80–$300. Monthly cost of the same drug in the USA: $4,000–$8,000. That is not a typo.

For long-term CML management, India doesn't just offer affordable care — it offers sustainable care that patients can actually continue for the years needed.

Chronic Lymphocytic Leukaemia (CLL) — The Watch-and-Treat Type

CLL is slow-growing. Many patients go months or years without needing any treatment — this is the standard "watch and wait" approach. But when treatment becomes necessary, Indian haematologists use the same protocols referenced in the NCI's cancer treatment guidelines — FCR chemotherapy, ibrutinib, venetoclax, and monoclonal antibodies.

And critically: if you're coming from a country where ibrutinib costs $15,000 a month, India's generic version of the same drug will change your financial picture completely.

Why Thousands of International Patients Choose India for Leukemia Treatment

Leukemia treatment in India is 65–80% cheaper than USA and UK — 2026 comparison data

We've found that most patients come to us with one primary question: "Is India really as good as they say?" And our honest answer is — at the right hospitals, yes.

Real Cost Comparison — India vs USA, UK and UAE

Indicative 2026 estimates. MediGoCare provides exact cost estimates for your specific case — free of charge, within 48 hours.

Same Drugs, Same Protocols — Just a Fraction of the Price

This is the part people often question. And it's a fair question. So here's the direct answer.

India's top cancer hospitals — Tata Memorial Centre, Medanta, Apollo, BLK-Max — use identical chemotherapy protocols to MD Anderson in Houston or The Christie in Manchester. They're treating 70,000+ patients a year, which gives their teams a level of case volume most Western hospitals can't match.

Most of these hospitals carry JCI (Joint Commission International) and NABH dual accreditation. And many of India's senior haematologists trained at UCL, Johns Hopkins, or the Karolinska Institute before returning to practise in India.

The drugs are the same. The protocols are the same. The price is not.

Treatment Starts in 2 Weeks — No NHS-Style Waiting

In the UK, average waiting time from cancer referral to treatment start is 62+ days. In Canada, it's often longer. In India, we routinely have patients walking into their first treatment appointment within 10–14 days of sending us their medical records.

For fast-moving cancers like ALL and AML, those weeks aren't administrative — they're clinical. They matter.

Leukemia Treatments Available in India Right Now

Full range of leukemia treatment options at India's top haematology hospitals — 2026

India offers every modern treatment modality for leukemia. No patient should assume they need to travel to the USA or Europe to access cutting-edge blood cancer care.

Chemotherapy — Still the Backbone

Chemotherapy is the foundation of leukemia treatment — especially for ALL and AML. Treatment follows three phases: induction (hitting the cancer hard and fast), consolidation (killing remaining cells), and maintenance (keeping the disease away, often for 2–3 years).

Indian hospitals use drugs like cytarabine, daunorubicin, vincristine, L-asparaginase, and methotrexate — the same agents used at leading oncology centres globally. Since India manufactures many of these drugs domestically, the cost per cycle is a fraction of what it is in import-dependent countries.

Targeted Therapy — Imatinib, Dasatinib & TKIs for CML and ALL

For CML and Philadelphia-positive ALL, TKI therapy is the international first-line standard. India's access to high-quality generics of imatinib, dasatinib, nilotinib, ponatinib, and bosutinib at $80–$300 per month is simply not available anywhere else in the world at this price point.

These drugs are bioequivalent to branded versions. They work the same way. They're produced under the same regulatory standards. And they make long-term CML management genuinely affordable.

Immunotherapy & Monoclonal Antibodies

Monoclonal antibody therapies — rituximab for B-cell leukaemias, blinatumomab (BiTE therapy) for relapsed ALL, obinutuzumab for CLL — are fully available at India's top oncology centres.

Blinatumomab in particular has transformed outcomes for patients with relapsed/refractory ALL who had very few remaining options. We've helped coordinate blinatumomab treatment for patients from Bangladesh and Ethiopia who couldn't afford it in their home countries. The outcomes were genuinely encouraging.

Learn about: Non-Hodgkin Lymphoma Treatment

Bone Marrow Transplant (BMT) for Leukemia

BMT offers the best chance of long-term cure for many leukemia patients — especially AML and ALL in second remission, and aplastic anaemia that runs alongside blood cancers.

India performs some of the highest BMT volumes in Asia. Both matched-donor allogeneic transplants and haploidentical (half-matched family donor) transplants are available. The haploidentical approach is particularly important — it means patients without a perfectly matched sibling can still access BMT using a parent, child, or partially-matched relative.

For everything about BMT costs, types and success rates, read our detailed guide: Bone Marrow Transplant in India — Cost, Types & Success Rates.

CAR-T Cell Therapy — India's Most Exciting New Option

Until recently, CAR-T therapy was only available in the USA and Europe. At $400,000–$600,000 a course, it was out of reach for almost every patient outside those countries.

India has changed that. NexCAR19 — India's own indigenously developed CAR-T therapy, approved by India's CDSCO regulator — is now available at Tata Memorial Mumbai and Medanta Gurgaon. The cost in India: $45,000–$100,000. That's the same science, the same clinical category, at 75–85% lower cost.

NexCAR19 is approved for relapsed or refractory B-cell ALL and large B-cell lymphoma. It's a major development — and one that most competing medical tourism websites haven't caught up with yet.

Full guide here: CAR-T Cell Therapy India — Cost, Eligibility & Hospitals.

Radiation Therapy — When It's Needed

Radiation isn't a first-line leukemia treatment, but it has specific roles. CNS prophylaxis (protecting the brain and spinal fluid from leukemia spread) sometimes uses cranial radiation in ALL protocols. Total Body Irradiation (TBI) is used as conditioning before certain bone marrow transplants. India's top oncology centres have modern linear accelerators and stereotactic radiosurgery systems for precision delivery.

Leukemia Treatment Cost in India 2026 — The Complete Breakdown

Complete leukemia treatment cost breakdown in India across all types — 2026 data

Cost by Treatment Type

Cost by City

What MediGoCare's Package Covers

Working with us doesn't add cost — it removes stress. Here's what we coordinate at no extra charge:

• Free haematologist second opinion before you book anything
• Doctor and hospital shortlist matched to your leukemia type and budget
• Official hospital invitation letter for e-Medical Visa application
• Airport pickup and accommodation near your treatment hospital
• Interpreter support (Arabic, French, Swahili, Hindi available)
• Cost estimate in 48 hours of receiving your medical records
• Discharge planning and fit-to-fly coordination
• Remote follow-up tele-consultations after you return home

Costs to Budget Beyond the Hospital Bill

We believe in full transparency. Budget additionally for: HLA typing for BMT donors (₹25,000–₹50,000), accommodation for family caregivers (₹50,000–₹1.5L per month), flights to and from India, incidental medications during treatment, and follow-up imaging once you're back home. We go through all of this in your free first consultation — no surprises later.

Best Hospitals for Leukemia Treatment in India

India's top JCI and NABH accredited hospitals for leukemia and blood cancer treatment

Leukemia Treatment Success Rates in India — What the Numbers Show

Success rates vary by type, patient age, and treatment centre. The figures below reflect outcomes at India's top-tier haematology hospitals — sourced from Tata Memorial Centre data, the ICMR National Cancer Registry, and peer-reviewed literature on PubMed.

For CML specifically, outcomes in India are essentially identical to the West. The disease responds to TKI drugs regardless of geography. For ALL and AML, outcomes at India's top five centres are within 5–10 percentage points of top US academic medical centres — a gap largely driven by late-stage presentations at diagnosis rather than treatment quality.

Childhood Leukemia Treatment in India — Paediatric ALL and AML

Paediatric ALL is one of oncology's great success stories. With the right treatment, 75–85% of children at India's top centres achieve long-term remission. That statistic matters enormously — because treatment choice directly influences where a child ends up in that range.

India's hospitals like Tata Memorial and Apollo have dedicated paediatric oncology wings. Chemotherapy dosing is weight-adjusted. Supportive care — nutrition support, play therapy, family accommodation — runs alongside clinical treatment. It's not just a hospital. It's a complete environment built around treating children.

We've coordinated paediatric leukemia cases from Bangladesh, Nepal, Nigeria and Tanzania. Every time, the concern parents carry is the same: "Will my child be safe so far from home?" The honest answer, based on what we've seen: yes. These hospitals treat children from dozens of countries every month. The teams are experienced, the protocols are robust, and the outcomes speak for themselves.

If your child has been diagnosed with ALL or AML, contact us now. We'll arrange a free paediatric haematologist opinion within 24 hours.